PubMed
Thymosin beta 4 and wound healing: a multifunctional peptide
Goldstein et al., 2010
Healing & RecoveryResearch OnlyA
TB-500
Thymosin Beta-4 Fragment
TB-500 is the active synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally present in virtually all human cells and critical to actin regulation, cell migration, and tissue regeneration. Research shows TB-500 promotes angiogenesis, reduces inflammation, improves tissue flexibility, and accelerates recovery from musculoskeletal injuries. Not FDA-approved; banned from 503A compounding pharmacies.
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 9
- Research grade
- A
- Experience
- 72
- Activity
- 75
Overall check-ins
Trackers & reports
Overview
About TB-500
TB-500 is the active synthetic fragment of thymosin beta-4 (Tβ4), a 43-amino acid protein naturally present in virtually all human cells and critical to actin regulation, cell migration, and tissue regeneration. Research shows TB-500 promotes angiogenesis, reduces inflammation, improves tissue flexibility, and accelerates recovery from musculoskeletal injuries. Not FDA-approved; banned from 503A compounding pharmacies.
- Category
- Healing & Recovery
- Regulatory status
- Research Only
- Also known as
- Thymosin Beta-4 Fragment
- Self-reports
- 103
Community
What 103 users report
103 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 38% · Mixed 62% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Recovery
219
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
70
Fatigue
65
Self-reported dose per injection
Median bucket: 2–3 mg · Most common: 2–3 mg
Reports span 0 to ≥ 5 mg (open-ended top bucket)
0–0.01 mg
14
0.025–0.05 mg
1
0.1–0.2 mg
1
0.2–0.4 mg
29
0.4–0.6 mg
25
0.6–1 mg
2
1–2 mg
5
2–3 mg
72
3–5 mg
45
5+ mg
25
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 57% said they felt similar to their last entry, 23% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 63 days · Based on 40 repeat reporters
Research
Cited research (7)
Source
PubMed
Myocardial regeneration: expanding the repertoire of thymosin β4 in the ischemic heart
Smart et al., 2012
ClinicalTrials.gov
Thymosin beta-4 studies on ClinicalTrials.gov
ClinicalTrials.gov, 2024
PubMed
Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications
Goldstein et al., 2012
PubMed
Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing
Li et al., 2007
PubMed
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
Mayfield et al., 2026
PubMed
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
Rahman et al., 2026
Tools
Explore more
Explore
More ways to learn about TB-500 from observational PeptIQ data.
Help
Frequently asked
What do PeptIQ users report about TB-500?
This page summarizes 103 anonymized self-reports from PeptIQ users who track TB-500, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for TB-500?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for TB-500?
7 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is TB-500 safe to use?
This wiki does not assess safety or recommend use. TB-500 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of TB-500?
This wiki summarizes observational community reports and linked citations for TB-500. It does not assert therapeutic benefits. See the cited research list on this page and the educational profile for TB-500 for study-level context — not medical advice.
What is the legal status of TB-500?
TB-500 is listed in PeptIQ as Research Only. Regulatory status varies by jurisdiction and can change. This wiki does not provide legal advice; check current FDA and local rules and talk with a licensed clinician or counsel for personal decisions.
What are the known or theoretical side effects and risks of TB-500?
Safety data quality for TB-500 varies widely by compound and study design. PeptIQ does not establish a risk profile here. Review primary literature, product labeling where applicable, and clinician guidance. Community self-reports are not a substitute for clinical evidence.
What is the current state of research on TB-500?
This page links 7 indexed sources for TB-500. Evidence maturity differs by application — some peptides have large human programs, others are mostly preclinical. Treat citation counts as literature volume, not proof of efficacy.